The pharmaceutical industry’s relationship with evidence is changing. Fast. Where randomized controlled trials once stood as the sole gold standard, real world evidence now sits at strategy tables alongside traditional clinical data — influencing everything from drug approvals to payer negotiations to portfolio decisions worth hundreds of millions.
If you’re leading HEOR, market access, or commercial analytics for a pharma company in 2025, you’ve likely noticed the acceleration. RWE isn’t just an emerging trend anymore. It’s infrastructure. The FDA finalized guidance in December 2025 expanding real-world evidence acceptance for medical device reviews. The EMA continues building out DARWIN EU with systematic pathways for regulatory-grade RWE. And your competitors? They’re already using claims data, linked EHR datasets, and predictive analytics to size markets, optimize launches, and demonstrate value to skeptical payers. For teams working with claims-based patient-level data, rigorous phenotype validation in claims data is the methodological step that determines whether your disease cohort accurately represents the population you intend to study.
Here’s what actually matters about the real world evidence market right now — not the buzzwords, but the strategic shifts reshaping how life sciences companies generate evidence and make decisions.
The Market That Doubled (Depending on Who You Ask)
Market sizing for RWE solutions varies wildly depending on definitions. Are we talking pure datasets? Analytics platforms? Full-service evidence generation? The scope matters because it determines what you’re actually buying.
Current estimates for 2025 place the global real world evidence solutions market somewhere between USD 2.4 billion and USD 20 billion. That’s not a typo — the range reflects fundamentally different methodologies. Grand View Research pegs it at USD 3.03 billion, focusing primarily on data licensing and analytics platforms. Fortune Business Insights estimates USD 20.03 billion, incorporating broader evidence generation services, consulting, and implementation support.
The discrepancy tells you something important about market maturity. RWE isn’t just data anymore — it’s evolved into a services-heavy ecosystem where pharma companies increasingly need integrated solutions, not just access to claims databases.
What everyone agrees on: growth trajectory. Projections consistently show CAGRs between 10-16% through 2030-2035, with MarketsandMarkets forecasting USD 10.83 billion by 2030 and Global Market Insights projecting USD 10.2 billion by 2034. For context, that’s faster growth than traditional clinical trial services.
Why RWE Stopped Being Optional
Three converging forces transformed real world evidence from academic curiosity to strategic imperative over the past five years.
First, the regulatory shift. The FDA didn’t just accept RWE in isolated cases — they systematized it. December 2025 guidance eliminated a major barrier by allowing de-identified patient data in submissions, addressing privacy concerns that historically limited RWE utility. The FDA’s Oncology Center of Excellence has approved multiple cancer drugs using external control arms derived from real-world data, demonstrating regulatory acceptance extends beyond post-market surveillance into core approval pathways.
Second, the payer equation changed. Value-based care isn’t a pilot program anymore. It’s how reimbursement works in major markets. Payers want evidence your drug performs in their populations — not just the highly selected patients who made it through Phase III inclusion criteria. Health technology assessment bodies across Continental Europe increasingly demand comparative effectiveness data that captures real-world adherence, switching patterns, and long-term outcomes.
Third — and this matters for commercial strategy — the data got better. A decade ago, claims data gave you diagnosis codes and prescription fills. Now? Linked claims-EHR datasets provide lab results, biomarker information, detailed treatment sequences, and longitudinal tracking across care settings. Analysis of FDA submissions from 2019-2021 shows increasing sophistication in how companies integrate multiple RWD sources for robust evidence generation.
What’s Actually Growing (And What Isn’t)
Not all RWE segments are created equal. If you’re allocating budget or evaluating vendors, understanding growth patterns reveals where the industry’s moving.
Datasets — particularly longitudinal claims databases and linked claims-EHR data — represent the fastest-growing segment. Mordor Intelligence projects dataset revenues will dominate, driven by demand for large-scale, analysis-ready data covering diverse therapeutic areas. The shift from “data as product” to “data as platform” is real. Companies aren’t just buying datasets; they’re licensing access to continuously updated, curated data environments with APIs, standardized schemas, and built-in analytics tools.
Services are the revenue engine. Full-service evidence generation — where specialized firms design studies, execute analyses, and deliver regulatory-ready outputs — captures the largest share of market spend. Why? Because most pharma companies still lack internal expertise to wrangle messy real-world data into credible evidence. Building in-house RWE capabilities requires epidemiologists, biostatisticians, data engineers, and regulatory specialists who understand what “fit-for-purpose” means to the FDA.
Oncology and rare diseases are pulling disproportionate investment. The FDA’s Oncology Real World Evidence Program has established clear pathways for using RWE in cancer drug development, from external control arms to accelerated approvals. In rare diseases, where traditional RCTs are impractical due to small patient populations, RWE becomes the primary evidence base. Disease registries and natural history studies using real-world data are increasingly accepted by regulators for label expansions and indication extensions.
Meanwhile, pure analytics software without data is struggling. Platforms that provide tools but require you to bring your own data face headwinds. The value is in integrated solutions — data + analytics + expertise. Here’s what Pharma teams get wrong about RWE.
The Three Data Sources That Actually Matter
When pharma companies talk about real world data, they’re really talking about three core sources. Everything else is supplementary.
Administrative claims data — insurance billing records from national health systems and private insurers — provides population-scale longitudinal information on treatment utilization, healthcare resource use, costs, and basic outcomes. Claims data dominates for pharmacoeconomic studies, market access negotiations, and post-marketing surveillance. Coverage can be substantial (often representing 70-90% of insured populations in developed markets), and longitudinal tracking enables analyses of treatment persistence, switching patterns, and real-world effectiveness over years.
The limitation? Clinical granularity. Claims tell you a patient filled a prescription, but not why they stopped. They show a hospitalization, but not disease severity markers or lab results critical for outcomes research.
Electronic health records (EHRs) fill that gap with detailed clinical data from healthcare providers: lab results, vital signs, physician notes, imaging reports, and treatment details. EHRs increasingly link with claims data to create richer, patient-level datasets that support effectiveness evaluations, subgroup analyses, and personalized medicine applications. The challenge is completeness — EHRs capture what happens within a healthcare system but miss care delivered elsewhere.
Patient and disease registries — structured databases focused on specific conditions or products — provide the highest-quality, most curated longitudinal data. Registries are particularly valuable for rare diseases, oncology, and situations requiring detailed clinical endpoints not reliably captured in claims or EHRs. They’re purpose-built for outcomes research, which makes them expensive to maintain but extremely valuable for regulatory submissions and label expansions.
The trend is toward linked datasets. Single-source data has inherent limitations, so sophisticated RWE strategies combine claims + EHRs + registries to mitigate weaknesses of each source. Linked data enables analyses that claims alone couldn’t support (like correlating biomarker status from EHRs with treatment outcomes from claims) while maintaining population-scale coverage.
Regulatory Acceptance: From Skepticism to Systematic Integration
The FDA’s evolution on RWE tells the story of broader regulatory acceptance. Early examples were isolated — a cancer drug approval here, a device review there. Now it’s systematic policy.
The December 2025 final guidance on RWE for medical devices represents a watershed. By explicitly accepting de-identified patient data and expanding pre-market and post-market applications, the FDA signaled that privacy concerns — historically the largest barrier — are now addressable through proper techniques. This matters beyond devices; the principles apply across therapeutic products.
Analysis of oncology drug approvals shows increasing FDA reliance on external control arms derived from RWD when single-arm trials are necessary for rare cancers or aggressive diseases where placebo arms are unethical. The key criterion is “fit-for-purpose” — does the RWD source match the clinical question, population, and evidentiary standard required?
The EMA parallels this evolution through DARWIN EU, their distributed data network initiative. The 3rd progress report covering February 2024 to February 2025 details growing experience with regulator-led RWE studies. Pilot regulatory use cases demonstrate successful integration of RWE for safety monitoring, effectiveness evaluations, and label updates.
What hasn’t changed: the bar for evidence quality. Regulatory-grade RWE requires transparent methodology, validated data sources, appropriate study design, and robust statistical methods to address confounding. “Real world” doesn’t mean “low quality.” If anything, regulators scrutinize RWE more carefully precisely because observational data lacks the control of RCTs.
How Pharma Actually Uses RWE Across the Lifecycle
Theory says RWE supports the entire product lifecycle. Practice shows four primary applications where companies invest most heavily.
Clinical development optimization uses RWD early in the pipeline for trial design, feasibility assessment, and patient recruitment strategy. Natural history studies inform appropriate endpoints and expected progression rates. Synthetic control arms — derived from real-world patient cohorts matching trial inclusion criteria — enable single-arm studies in settings where randomized controls are impractical. The ROI here is substantial: better-designed trials with realistic enrollment timelines.
HEOR and comparative effectiveness represents the largest RWE use case by spend. Health economics teams use real-world data to demonstrate cost-effectiveness, quality-adjusted life years gained, and comparative performance versus standard of care. These analyses inform pricing negotiations, HTA submissions to bodies like NICE or IQWiG, and value-based contracting with payers. The evidence needs to withstand payer scrutiny — which means rigorous methodology, sensitivity analyses, and transparent handling of confounders.
Market access and reimbursement increasingly depends on real-world performance data. Payers want evidence your drug works in their populations, including patients with comorbidities typically excluded from trials. RWE supports formulary placement, step-edit justifications, and outcomes-based risk-sharing agreements where payment depends on real-world outcomes. This is where longitudinal data becomes critical — you need years of follow-up to demonstrate durable benefit.
Post-market surveillance and pharmacovigilance uses RWE for safety monitoring, rare adverse event detection, and label updates. Claims databases covering millions of patients enable detection of safety signals that wouldn’t emerge in limited-duration trials. This satisfies regulatory post-approval commitments while providing competitive intelligence on safety profiles versus alternatives.
The sophistication gap between companies is widening. Leading pharma organizations have built Centers of Excellence with dedicated RWE teams spanning epidemiology, biostatistics, health economics, and regulatory strategy. They’ve invested in platforms providing continuous access to refreshed data, not one-off studies. Others still approach RWE reactively, commissioning analyses when a payer demands evidence rather than building systematic capabilities.
Understanding Your Data Partnership Options
The challenge many pharmaceutical companies face isn’t finding data providers — it’s determining which combination of capabilities aligns with their strategic priorities. The data landscape includes dozens of specialized firms with overlapping but distinct strengths across several critical dimensions.
Coverage and scale: Population coverage varies dramatically. Some providers maintain comprehensive longitudinal records covering hundreds of millions of patient lives across multiple regions and payer types, while others focus on specific geographies or therapeutic areas with greater clinical depth. The choice depends on whether you need broad market intelligence or specialized patient populations.
Analytical sophistication: Capabilities range from traditional query-based systems to AI-powered platforms offering real-time pattern recognition and predictive analytics. Some providers offer self-service tools for in-house teams, while others deliver full-service evidence generation with epidemiologists and biostatisticians handling study design and execution. The decision hinges on whether you need descriptive intelligence or forward-looking insights — and whether you have the internal expertise to conduct analyses yourself.
Data integration: Some sources combine claims with complementary data streams — lab results, specialty pharmacy utilization, provider characteristics, social determinants of health — for richer patient profiles. This vertical integration creates analytical possibilities that pure claims data cannot support. Others maintain focused datasets optimized for specific use cases like oncology treatment pathways or rare disease natural history.
Data recency and refresh: Update frequency matters for time-sensitive applications. Some providers offer near-real-time adjudicated claims for commercial intelligence, while others focus on historically deep datasets ideal for epidemiology and outcomes research. The gap between data collection and analytical availability can range from weeks to years.
Cost models: Pricing structures vary from per-query licensing to annual platform subscriptions to full-service project fees. Understanding total cost of ownership — including data engineering, validation, and analytical labor — requires looking beyond headline licensing fees.
Navigating this landscape requires expertise in both pharmaceutical commercialization and the evolving real-world evidence ecosystem. The gap between understanding what claims data can theoretically provide and identifying which specific combination of capabilities matches your needs is substantial. Understanding which data sources match specific use cases requires deep market knowledge that most companies lack internally.
The Persistent Challenges No One’s Really Solved
For all the growth and sophistication, fundamental challenges remain. These are the pain points that drive strategic decisions about RWE implementation.
Data quality and completeness tops every list. Real-world data is messy by definition — it’s collected for billing and care delivery, not research. Missing values, coding inconsistencies, unstructured clinical notes, and temporal gaps between data sources create substantial data engineering burdens. Claims might show a diagnosis code, but was it accurate? EHRs capture lab results, but are units standardized? The “80/20 rule” applies: 80% of RWE project time goes to data cleaning and validation, 20% to actual analysis.
Privacy and data access barriers persist despite regulatory evolution. GDPR compliance requirements in Europe, HIPAA in the US, and similar frameworks globally create complex requirements for data use and sharing. Even with recent FDA acceptance of de-identified data, creating truly anonymized datasets while preserving analytical utility remains technically challenging. Tokenization and other privacy-preserving techniques add cost and complexity.
Bias and confounding — the inherent limitation of observational data — requires sophisticated statistical approaches. Patients who receive a drug in the real world differ systematically from those who don’t. Controlling for these differences through propensity scoring, instrumental variables, or causal inference methods is methodologically complex and computationally intensive. And even the best methods can’t adjust for unmeasured confounders.
Payer and HTA mistrust remains a barrier to RWE impact. Many payers view real-world studies as supplementary to RCT evidence, not equivalent. Concerns about bias, generalizability, and sponsorship (most RWE studies are company-funded) create skepticism that robust methodology alone doesn’t fully overcome. Building payer confidence requires transparency, independent validation, and demonstrated track record.
Standardization gaps across data models, terminologies, and study methodologies hinder reproducibility and comparison. While initiatives like OHDSI’s OMOP common data model help, adoption remains incomplete. Different providers use different schemas, making cross-platform analyses difficult.
Equity and representation concerns are growing. RWD sources often underrepresent diverse populations, rural patients, and those with limited healthcare access. Evidence generated from incomplete populations may not reflect true real-world performance across all patient segments, particularly for drugs treating conditions with disparate impact.
These aren’t insurmountable, but they’re also not going away quickly. Companies with realistic expectations about RWE limitations — and strategies to address them — gain competitive advantage. Expert advisors who understand both your business objectives and the data landscape can accelerate your path to value while avoiding common pitfalls in vendor selection and implementation.
Where This Goes Next
Three trends are reshaping what “real world evidence” means and how it’s used.
AI and machine learning integration is accelerating. Not just for predictive analytics, but for automated data curation, confounding adjustment, and evidence synthesis. Large language models show promise for extracting structured data from clinical notes at scale. But algorithmic transparency and validation remain critical — black-box AI won’t satisfy regulatory scrutiny.
Decentralized and patient-generated data is expanding beyond traditional sources. Wearables, mobile health apps, and patient-reported outcomes collected continuously in real-world settings provide new dimensions of evidence. The challenge is validation — how do you ensure data quality from consumer devices? And integration — how do you link patient-generated data with clinical and claims records?
Global harmonization of RWE standards and regulatory frameworks is progressing slowly but meaningfully. As more health authorities accept RWE, consistent approaches to study design, data quality, and evidence appraisal become possible. This enables multinational pharma companies to develop unified RWE strategies rather than country-specific approaches.
The ultimate trajectory: RWE becomes embedded infrastructure rather than special project. Just as clinical trial data flows through structured systems and processes, real-world data will integrate systematically into evidence generation, regulatory interaction, and commercial strategy. The companies that figure this out first — building capabilities, platforms, and expertise now — gain years of competitive advantage in markets where evidence speed and quality determine success.
What This Means for Your RWE Strategy
If you’re responsible for HEOR, market access, or evidence generation, a few implications matter immediately.
Build capabilities, don’t just buy studies. One-off RWE analyses deliver point-in-time answers. Systematic capabilities — platforms, team expertise, strategic partnerships — enable continuous evidence generation across your portfolio. The ROI difference is substantial.
Invest early in understanding regulatory standards. “Fit-for-purpose” isn’t a buzzword; it’s the FDA’s framework for evaluating RWE. Know what data quality, study design, and analytical rigor your regulatory pathway requires before commissioning expensive studies.
Think linked datasets, not single sources. Claims alone miss clinical context. EHRs alone miss care outside a system. Registries alone lack scale. Sophisticated evidence requires integrated data from multiple sources with proper linkage methodology.
Define requirements before evaluating options. Document your coverage needs (geographies, therapeutic areas, patient populations), analytical capabilities (self-service vs. full-service), integration requirements (API access, data formats), compliance constraints, and budget parameters. This clarity prevents costly mismatches between what you need and what providers offer.
Leverage expert guidance for data partnership selection. The gap between licensing claims data and extracting actionable intelligence is substantial — this is where expert guidance becomes critical. Advisors who understand both pharmaceutical commercialization and the evolving vendor landscape can help you avoid the most common implementation pitfalls while accelerating time-to-value.
Start payer conversations early with RWE. Don’t wait until reimbursement negotiations to discuss real-world evidence. Engage payers during development about what evidence they’d find credible. Co-design studies when possible. Evidence payers help design is evidence they trust.
The real world evidence market isn’t just growing. It’s maturing into essential pharma infrastructure. The companies treating RWE as core capability rather than occasional tactic are the ones defining what evidence looks like for the next decade.
Ready to Navigate the RWE Landscape?
Understanding what types of real-world evidence exist and what questions they can answer is the first step. The second step — matching your requirements to the right combination of data sources, analytical capabilities, and implementation approaches — requires guidance from professionals who understand both the pharmaceutical industry and the complex RWE ecosystem.
The challenge isn’t finding data providers. It’s determining which capabilities align with your strategic priorities, avoiding costly mismatches, and building sustainable evidence generation systems that deliver value across your portfolio.
Contact us to explore strategic approaches to real-world intelligence that align with your business objectives and regulatory requirements.
Sources & References
- MarketsandMarkets (2025). Real World Evidence Solutions Market Growth, Drivers, and Opportunities. https://www.marketsandmarkets.com/Market-Reports/real-world-evidence-solution-market-76173991.html
- Grand View Research (2025). Real World Evidence Solutions Market | Industry Report, 2033. https://www.grandviewresearch.com/industry-analysis/real-world-evidence-solutions-market-report
- Fortune Business Insights (2025). Real World Evidence Solutions Market | Global Report, 2032. https://www.fortunebusinessinsights.com/real-world-evidence-solutions-market-107676
- U.S. Food and Drug Administration (December 2025). Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices: Guidance for Industry and Food and Drug Administration Staff. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-real-world-evidence-support-regulatory-decision-making-medical-devices
- FDA Press Announcement (December 15, 2025). FDA Eliminates Major Barrier to Using Real-World Evidence in Drug and Device Application Reviews. https://www.fda.gov/news-events/press-announcements/fda-eliminates-major-barrier-using-real-world-evidence-drug-and-device-application-reviews
- European Medicines Agency (2025). Real-world evidence framework to support EU regulatory decision-making: 3rd report on the experience gained with regulator-led studies from February 2024 to February 2025. https://www.ema.europa.eu/en/documents/report/real-world-evidence-framework-support-eu-regulatory-decision-making-3rd-report-experience-gained-regulator-led-studies-february-2024-february-2025_en.pdf
- Feinberg BA, et al. (2020). Use of Real-World Evidence to Support FDA Approval of Oncology Drugs. Value in Health, 23(10):1358-1365. https://www.sciencedirect.com/science/article/pii/S1098301520322026
- Purpura CA, et al. (2022). The Role of Real-World Evidence in FDA-Approved New Drug and Biologics License Applications. Clinical Pharmacology & Therapeutics. https://pmc.ncbi.nlm.nih.gov/articles/PMC9299054/
- Prilla et al. (2024). Real-World Evidence to Support EU Regulatory Decision Making—Results From a Pilot of Regulatory Use Cases. Clinical Pharmacology & Therapeutics. https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3355
- Mordor Intelligence (2025). Real-World Evidence Solutions Market Size, Trends | Share Analysis 2030. https://www.mordorintelligence.com/industry-reports/real-world-evidence-solutions-market
- Global Market Insights (2025). Real World Evidence Solutions Market Size & Forecast 2034. https://www.gminsights.com/industry-analysis/real-world-evidence-solutions-market
- FDA Oncology Center of Excellence. Oncology Real World Evidence Program. https://www.fda.gov/about-fda/oncology-center-excellence/oncology-real-world-evidence-program